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Neisseria meningitidis (the meningococcus) is a leading
cause of meningitis and septicaemia. The meningococcal
ST-11 clonal complex (cc11) is diverse, comprised of two
main lineages (lineage 11.1 and lineage 11.2; also known
as sublineages 11.1 and 11.2), and includes serogroups C
(MenC), W (MenW) and, to a lesser extent, B (MenB).1,2 It
is associated with relatively high case fatality rates and
has been the cause of numerous large outbreaks including
MenC cc11 (C:cc11) disease in the US military in the
1960s3 and educational institutions at a time of heightened
endemic disease in the UK and elsewhere in the 1990s.4,5
Outbreaks due to C:cc11 have recently been reported
among men who have sex with men (MSM) in Europe and
America.6 MenW cc11 (W:cc11) was the cause of a global
outbreak among Hajj pilgrims in 2000 and has subsequently
caused epidemics in the African meningitis belt and
increased endemic disease in South Africa, South America,
Europe and Australia.7
The UK and other countries responded to the increase in
C:cc11 disease in the 1990s/2000s with highly effective
glycoconjugate vaccination campaigns.8 More recently,
Chile and the UK introduced quadrivalent meningococcal
conjugate vaccination (MenACWY) to combat the increase
in W:cc11 cases, an intervention being considered by other
countries also experiencing a national W:cc11 outbreak.9,10
There were concerns about capsular replacement from
MenC to MenB during the MenC vaccine campaigns, espe-
cially given that the poor immunogenicity of the MenB poly-
saccharide precludes the development of MenB
polysaccharide-based vaccines.11 Large modern MenB cc11
(B:cc11) outbreaks have yet to occur, however, an increase
in cases was reported in France after 2002.12 Furthermore,
a recent study indicated multiple capsular switching events
within cc11, with MenB and MenC organisms highly inter-
spersed within multiple lineage 11.1 and 11.2 sublineages.1
Several non-capsular vaccines have been developed to
prevent MenB disease. Monovalent outer membrane vesicle
(OMV) preparations are generally strain-specific due to the
immunodominance of the diverse but poorly cross-
protective porin A (PorA). Monovalent OMV preparations
have targeted meningococci with PorA subtypes P1.7,16,
P1.7-2,4, P1.19,15 and P1.3.13,14 Multivalent OMV vaccines
have also been proposed including a serogroup A þ W
OMV vaccine incorporating PorA subtypes P1.20,9 and
P1.5,2,15 and a nine-valent formulation including PorA sub-
types P1.7,16, P1.22,14, P1.5-1,2-2, P1.5-2,10, P1.7-1,1,
P1.12-1,13, P1.19,15-1, P1.7-2,4 and P1.18-1,3.16
The 4CMenB vaccine includes an OMV (PorA P1.4) and
three main protein antigens e factor H-binding protein(fHbp), Neisseria adhesin A (NadA) and neisserial heparin
binding antigen (NHBA).17 The fHbp variant 1 component
potentially protects against meningococci expressing fHbp
variant 1, but not variant 2 or 3, peptides. The NadA variant
2/3 component potentially protects against meningococci
with variant 1 or variant 2/3 NadA, but not variants 4, 5
or 6. Potential cross-protectivity afforded by the NHBA
component is less well understood. Actual strain coverage
by the vaccine depends on the antigenic similarity and/or
expression level of the respective antigen within the infect-
ing organism. The Meningococcal Antigen Typing System
(MATS) is an ELISA that collectively measures both of these
qualities to predict strain coverage afforded by the 4CMenB
vaccine.18 Large scale studies incorporating MATS are
contributing to our knowledge of potential 4CMenB
coverage by virtue of specific peptide variants of the indi-
vidual vaccine antigens within the study populations.19,20
The bivalent fHbp vaccine, rLP2086, comprises variant 1
and variant 3 fHbp peptide components, the latter of which
may be cross-protective against meningococci with variant
2, as well as those with variant 3, peptides.21 Strain
coverage afforded by the bivalent fHbp vaccine is predicted
using the Meningococcal Antigen Surface Expression (MeA-
SurE) flow cytometric assay which quantifies fHbp surface
expression.22
None of these vaccines are likely to protect against all
MenB strains. The aim of this study was to assess genotyp-
ically the potential of these vaccines to protect against
B:cc11 meningococci.Materials and methods
Genomes
Genomes and typing data were obtained from the PubMLST
Neisseria database (https://pubmlst.org/neisseria, ac-
cessed 07/10/16)23 and the Meningitis Research Foundation
Meningococcus Genome Library (http://www.meningitis.
org/research/genome, accessed 07/10/16) the latter of
which contains all English, Welsh and Northern Irish invasive
disease isolates received by the Public Health England
Meningococcal Reference Unit from July 2010 onwards.
Owing to a paucity of MenB genomes among the MenW-
associated lineage 11.1 sublineages, all corresponding ge-
nomes, irrespective of capsular group, were excluded from
the analysis (Supplementary figure). With a single excep-
tion, relatively poorly sequenced/assembled genomes
comprising more than an arbitrary cut-off of 500 contigs
were also omitted from the study. The exception, M16
240144 (624 contigs), was included for completeness of the
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The final panel (n Z 900; supplementary information)
included all remaining cc11-assigned genomes and those
with incomplete MLST profiles that matched the ST-11 pro-
file at more than four loci. It also included that of the recent
English isolate M16 240518 (MenC cc11; submitted after 07/
10/16) and two non cc11 ‘reference’ genomes (PubMLST IDs
27778 and 29645; cc41/44 and cc8, respectively).
The B:cc11 genomes (n Z 89; of which 78 invasive, 3
carrier, and 8 other/unspecified) were from isolates
collected in the UK (nZ 50; 1970 to 2016), Czech Republic
(n Z 26; 1984 to 2011), France (n Z 5; 2014 to 2016),
Ireland (n Z 2; 2014) and one each from Greece (1998),
Norway (1969), Slovenia (2013), USA (1964), Tunisia (1987)
and Saudi Arabia (1998). The remaining genomes included
MenC isolates from 22 countries on five continents (nZ 763,
1970 to 2016), MenW isolates from South Africa and the USA
(n Z 3, 2005 and 2012), a MenY isolate of unknown origin
(n Z 1) and isolates from various countries that were non-
groupable or serogroup-unspecified (n Z 42, 1993e2016).
Molecular typing and phylogenetic network
analyses
Genomes were compared for 1546 core genes using the
PubMLST genome comparator tool.23e25 Distance matrices
were visualised using SplitsTree4.26 Untagged nadA or
nhba alleles that were incompletely assembled due to the
presence of an insertion sequence (IS) were identified by
searching known interrupted alleles using the BLAST algo-
rithm and aligning hits with the corresponding insertion
sequence.
MATS analyses
Isolate-specific MATS data for English invasive B:cc11 iso-
lates from 2007/8 were obtained from a previous study.19
An isolate was predicted to be covered by 4CMenB (MATS-
positive) if one or more of fHbp, NadA or NHBA had a rela-
tive potency (RP) greater than the positive bactericidal
threshold (PBT; 0.021 for fHbp, 0.009 for NadA, and 0.294
for NHBA), and/or the isolate possessed PorA P1.4.
Results
The MenB genomes from Tunisia and Saudi Arabia
(PubMLST IDs 34577 and 34596) were found to cluster
with cc8 isolates and were disregarded for the remainder
of the study. The remaining MenB genomes were distrib-
uted between lineages 11.1 (nZ 10; 1964e2014) and 11.2
(n Z 77; 1970e2016) where they were broadly inter-
spersed among the remaining predominantly MenC ge-
nomes (Fig. 1). Several predominantly MenB clusters were
also observed.
Lineage 11.1 MenB genomes
There were ten lineage 11.1 MenB genomes. Four of these
(all P1.5-1,2-2:ST-3537) were closely related within a
distinct sublineage and possessed alleles encoding variant2 fHbp peptides and NHBA peptide 20, and were devoid of a
nadA gene. The remaining six genomes (all P1.5,2:ST-11)
were interspersed with MenC genomes within several
distinct clusters and possessed alleles encoding variant 2
or 3 fHbp peptides, NHBA peptide 29, and NadA-2/3 pep-
tides (Fig. 1).
Lineage 11.2 MenB genomes
The 77 lineage 11.2 MenB genomes were broadly inter-
spersed with MenC genomes within multiple clusters and
subclusters (Fig. 1). The main PorA subtypes were P1.5-
1,10-8 (n Z 41) and P1.5,2 (n Z 27). The remaining PorA
subtypes included P1.5-1,10-1 (n Z 2), P1.7-1,1 (n Z 2)
and a single genome each for P1.17,16-3, P1.5,2-53, P1.5-
1,10-4, P1.5-1,2-2 and P1.5-2,10. All of the lineage 11.2
MenB genomes possessed alleles encoding NHBA peptide
20. Based on their corresponding fHbp variant, these fell
into the following three subgroups:
 Sixty-two percent (48/77) possessed alleles encoding
variant 1 fHbp peptides including peptides 10 (n Z 8),
2 (nZ 4), 453 (nZ 4), 78 (nZ 3) and a further 22 other
peptides (n  2 isolates each). Of these, eight possessed
alleles for NadA-2/3 peptides, 38 possessed insertionally
inactivated or frameshifted nadA alleles, one possessed
an incompletely assembled nadA allele (assembly arte-
fact) and one was devoid of a nadA allele.
 Twenty-five percent (19/77) possessed alleles for
variant 2 or 3 fHbp peptides including peptides 18
(n Z 9), 22 (n Z 3), 92 (n Z 2), 134 (n Z 2) and three
other peptides (n Z 1 isolate each). Of these, two
possessed alleles for NadA-2/3 peptides, 14 possessed
insertionally inactivated nadA alleles, and three were
devoid of nadA alleles.
 Thirteen percent (10/77) possessed frameshifted fhbp
alleles. Of these, three possessed alleles for NadA-2/3
peptides while the remaining seven possessed inser-
tionally inactivated nadA alleles.Distribution of minimally/non-vaccine-covered
MenB and MenC cc11 isolates
Approximately one third (28/87) of all of the MenB isolates
(from four countries between 1970 and 2014), and 17%
(128/763) of all of the MenC isolates (from 14 different
countries between 1970 and 2016) were potentially covered
by virtue of a single 4CMenB antigen which was NHBA. With
the exception of ten of the MenC isolates, these all
possessed alleles for NHBA peptide 20. The remaining ten
MenC isolates possessed alleles for NHBA peptides 29
(n Z 8), 118 (n Z 1) and 716 (n Z 1). The MenB isolates
were widespread within lineage 11.2, with some clustering,
but were only observed in a single cluster within lineage
11.1 (Fig. 2). The MenC isolates were relatively widespread,
including several lineage 11.1 clusters, but mainly belonged
to lineage 11.2 (Fig. 2). Three diverse lineage 11.2 MenC
isolates from the UK between 2000 and 2015 were pre-
dicted not to be covered by immunity against any of the
4CMenB antigens due, in part, to frameshifted or
Figure 1 Population structure and capsular group distribution among meningococcal ST-11 complex genomes belonging to
serogroup B/C-dominated lineage 11.1 and 11.2 sublineages. The scale bar indicates the number of differences among the 1546
core genome loci compared. NB lineage 11.1 and lineage 11.2 are also known as sublineage 11.1 and sublineage 11.2,
respectively.1,2
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isolates had similarly disrupted nhba alleles but were pre-
dicted to be covered by the immune response to other
4CMenB antigens (USA, 2006 and Canada, 2001/2).
Thirteen percent (10/77) of the MenB lineage 11.2
isolates (from four countries between 1998 and 2014) and
12% (62/535) of the MenC lineage 11.2 isolates (from ten
countries between 1996 and 2016) possessed frameshifted
fhbp alleles and so were unlikely to be covered by fHbp-
induced antibody. These isolates were widespread
throughout the lineage 11.2 population structure (Fig. 3).B:cc11 cases in England and Wales from 2010/11 to
2015/16
There were 16 B:cc11 cases in England and Wales between
2010/11 and 2015/16 with between zero and six cases
annually (Fig. 4). Among these, 12.5% (2/16) were due to
lineage 11.1 isolates, one with PorA subtype P1.5,2 and al-
leles for NHBA peptide 29, a variant 2 fHbp peptide and a
NadA-2/3 peptide; and the other with PorA subtype P1.5-
1,2-2 and alleles for NHBA peptide 20, a variant 2 fHbp pep-
tide and no nadA gene.
Figure 2 Diversity of MenB and MenC cc11 isolates potentially covered by zero or one 4CMenB antigen. MenB isolates potentially
covered by zero or one 4CMenB antigens were diverse but mainly belonged to two large clusters in lineage 11.2. The minimally/
non-covered MenC isolates were more widespread within the population but also predominantly belonged to lineage 11.2. NB line-
age 11.1 and lineage 11.2 are also known as sublineage 11.1 and sublineage 11.2, respectively.1,2
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11.2 organisms all of which had alleles for NHBA peptide 20.
Of these 93% (13/14) were subtype P1.5,2 and 7% (1/14) were
subtype P1.7-1,1. Seventy-one percent (10/14) of the lineage
11.2 isolates had alleles for variant 1 fHbp peptides (encoding
nine different peptides in total), including four with alleles
for NadA-2/3 peptides and six with insertionally inactivated
nadA alleles. Seven percent (1/14) possessed an allele for a
variant 2 fHbp peptide and had an insertionally inactivated
nadA allele. The remaining 21% (3/14) of the lineage 11.2 iso-
lates had frameshifted fhbp alleles, two with intact NadA2/3
alleles and one with insertionally inactivated nadA.
The case fatality rate among these cases was 31.3% (5/
16) and included 0/3 infants, 2/6 1e5 year-olds, 2/6 adults
(18e64 y) and 1/1 older adults.
B:cc11 MATS analyses
All six B:cc11 isolates from England in 2007/8 were
predicted by MATS to be killed by post-vaccination serum
samples (MATS-covered). One had RP > PBT for fHbp, NadA
and NHBA; one had RP > PBT for fHbp and NHBA, two had
RP > PBT for NadA and NHBA; and two had RP > PBT for
NHBA only. None of them possessed PorA P1.4 (Table 1).
Discussion
Large-scale capsule replacement did not occur following
the introduction of MenC glycoconjugate vaccination11;however, the recent W:cc11 outbreak affecting South
America, Europe and elsewhere highlighted the unpredict-
able nature of meningococcal outbreaks. This also empha-
sises the propensity of members of cc11, expressing
different serogroups, to cause outbreaks of aggressive inva-
sive disease.7 Here, in agreement with previous work,27,28
we found that B:cc11 in England and Wales was associated
with high case fatality rates and we provide further evi-
dence that diverse invasive B:cc11 organisms have been
generated on multiple occasions through capsular switching
of MenC organisms.1,12 Furthermore, the existence of
several persistent B:cc11 sublineages indicate that such
populations are not necessarily transient. All major
W:cc11 lineages are believed to have arisen from a common
capsule switch event.29 Fortunately, conjugate vaccines
were available to combat the recent W:cc11 outbreak,
while the recently licensed 4CMenB vaccine was also likely
to afford protection to infants against the outbreak
strain.30 This poses the question, however, that - if one of
these diverse MenB sublineages should expand to cause a
large outbreak, would currently available non-capsular
MenB vaccines afford protection?
The B:cc11 isolates were all potentially covered by
immunity to the NHBA component of 4CMenB, but none
were potentially covered by immunity to the PorA P1.4
component. None of the Lineage 11.1 isolates were poten-
tially covered by the 4CMenB fHbp component, but some
were potentially covered by immunity to the NadA compo-
nent. Collectively, the lineage 11.2 MenB isolates possessed
Figure 3 Diversity of MenB and MenC cc11 isolates with frameshifted fhbp alleles. The MenB and MenC isolates with frameshifted
fhbp alleles were widespread within lineage 11.2. NB lineage 11.1 and lineage 11.2 are also known as sublineage 11.1 and subline-
age 11.2, respectively.1,2
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variants, as well as some isolates with frameshifted fhbp al-
leles, as has been described previously.31,32 Similarly, the
presence of intact alleles for potentially covered NadA-2/
3 peptides was sporadic among lineage 11.2 MenB isolates.
Thus, from a genotypic standpoint, 4CMenB had the poten-
tial to protect against all of the MenB isolates by virtue of at
least one vaccine antigen and this was supported by MATS
results for the seemingly typical panel of six lineage 11.2
isolates from 2007/8.19 MATS is believed to provide a0
1
2
3
4
5
6
7
2010/11 2011/12 2012/13
n
epidemio
Figure 4 Distribution of B:cc11 lineage 11.1 and 11.2conservative estimate of strain coverage.19 In a recent
study of w500 students, however, a third did not exhibit
an hSBA response against a MATS-positive outbreak strain
eight weeks following their second dose of 4CMenB.33
In the present study, potential 4CMenB coverage among
many MenB isolates was limited to that afforded by the
NHBA component. These isolates possessed alleles for NHBA
peptide 20 which exhibited relatively high levels of MATS
coverage in two large studies.19,20 It is, however, of concern
that there were seven MenC genomes with disrupted nhba2013/14 2014/15 2015/16
logical year
Lineage 11.1 (ET-37) lineage 11.2 (ET-15)
genomes in England and Wales, 2010/11 onwards.
Table 1 MATS coverage among English B:cc11 isolates in 2007/8.
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and insertionally inactivated nadA alleles. The gene encod-
ing the NHBA peptide may, therefore, be dispensable for
lineage 11.2 organisms, as appears to also be the case for
NadA and fHbp. Furthermore, the diversity of fHbp among
lineage 11.2 isolates suggests a lack of immunological con-
straints, as has been proposed for other antigens,34 which
adds to the variant 1 fHbp vaccine component’s vulnera-
bility to vaccine escape.
In terms of other non-capsular vaccines, the bivalent
fHbp vaccine, rLP2086, would potentially cover the major-
ity of the B:cc11 meningococci but not those with a
frameshifted fhbp gene. It would also be particularly
vulnerable to vaccine escape owing to the apparent
dispensability of fhbp among diverse lineage 11.2 meningo-
cocci, given that this is the sole antigen in the vaccine.
None of the monovalent OMV vaccines or the nine-valent
vaccine included exact matches to either of the predomi-
nant PorA subtypes (P1.5,2 or P1.5-1,10-8).13 The protec-
tive potential of matching or closely-related VR1s (P1.5-1
or P1.5-2), or the closely-related VR2 (P1.2-2), of the
nine-valent vaccine against these isolates is not known. A
previous study has shown VR2 to be the main target for
the immune response against PorA P1.7-2,4.35 Cross-
protectivity of the immune response against PorA, mean-
while, may be dependent on the number of doses and ageof the vaccinee.36 Four PorAs contained in the nine-valent
vaccine did, however, constitute rare PorAs among the
B:cc11 isolates and may be useful if an outbreak were
caused by a rare strain.16 The investigational serogroup
A þ W OMV vaccine did include an exact match to one of
the predominant PorA subtypes (P1.5,2) and so may offer
protection depending on the emergent strain.15 The extent
of possible protection afforded by non-PorA OMV compo-
nents of these vaccines,13 or indeed that of Bexsero, among
these isolates is not known.
With the exception of the recent English, Welsh and
Northern Irish isolates, the dataset analysed here was
largely opportunistic and not globally comprehensive and,
as such, percentages provided in the results should be used
with caution. The important thing to note, however, is that
a number of geo-temporally and evolutionarily diverse
B:cc11 and C:cc11 isolates are minimally/not covered
and/or are able to dispense with genes for key antigens.
The number of MenB isolates, their overall geo-temporal
diversity, and their diverse antigenic repertoires, adds to
the strength of the conclusions. Future genomic character-
isation of large carriage strain panels37 will provide further
information on the underlying diversity of cc11 and supple-
ment these data. The data for England and Wales from
2010/11 onwards were comprehensive in terms of disease
isolates submitted to the MRU. There was no trend for
102 J. Lucidarme et al.increase of B:cc11 cases and the majority of these (nZ 12/
16) were potentially covered by virtue of two 4CMenB anti-
gens. On the other hand, it was noteworthy that the poten-
tial coverage of the remainder of the isolates was by virtue
of just one antigen. Furthermore, three out of 16 isolates
had fhbp alleles that were inactivated by frameshift muta-
tions and one of these was an isolate with an interrupted
nadA allele.
In conclusion, in the event of the public health emer-
gency that a large B:cc11 outbreak would represent, it may
not be possible to intervene as rapidly as with the W:cc11
outbreak, due to the absence of a suitable vaccine,
although there may be other vaccines in development
that were not discussed in the present manuscript. Any
protection afforded by the MenB vaccines available at the
time of writing may be vulnerable to vaccine escape.
Several previously employed or investigational OMV vac-
cines could provide a contingency response but rapid
availability would be unlikely, especially for investigational
vaccines that require further evaluation. Therefore it
would be prudent to investigate the inclusion of relatively
stable B:cc11 surface antigen variants in future MenB
vaccine formulations. Such candidates would include PorA
subtypes P1.5,2 and P1.5-1,10-8.
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